Despite high clinical utility of cilostazol, its underlying mechanism is an indirect inhibition of TRPC6 channel activity and endogenous activity of phosphorylating TRPC6 in VSMCs which could be decreased by various environmental changes, including endothelial dysfunction, hyperglycaemia and ageing. The gene discussed is TRPC6; the disease is endothelial dysfunction.